DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Plasbumin-5 (Albumin) - Description and Clinical Pharmacology

 
 



DESCRIPTION

Albumin (Human) 5%, USP (Plasbumin®-5) is made from pooled human venous plasma using the Cohn cold ethanol fractionation process. Part of the fractionation may be performed by another licensed manufacturer. It is prepared in accordance with the applicable requirements established by the U.S. Food and Drug Administration.

Plasbumin-5 is a 5% sterile solution of albumin in an aqueous diluent. The preparation is stabilized with 0.004 M sodium caprylate and 0.004 M acetyltryptophan. The approximate sodium content of the product is 145 mEq/L. It contains no preservative. Plasbumin-5 must be administered intravenously.

Each vial of Plasbumin-5 is heat-treated at 60°C for 10 hours against the possibility of transmitting the hepatitis viruses.

CLINICAL PHARMACOLOGY

Plasbumin-5 is oncotically equivalent volume for volume to normal human plasma.

When administered intravenously to an adequately hydrated subject, the oncotic (colloid osmotic) effect of Plasbumin-5 is to expand the circulating blood volume by an amount approximately equal to the volume infused. It is primarily used in the treatment of shock associated with hemorrhage, surgery, trauma, burns, bacteremia, renal failure, and cardiovascular collapse.1

Albumin is a transport protein and it may be useful in severe jaundice in hemolytic disease of the newborn.2 This could also be of importance in acute liver failure where albumin might serve the dual role of supporting plasma oncotic pressure, as well as binding excessive plasma bilirubin.1

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014